Related Experiment Video
Updated: Aug 15, 2026
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies
T Lavabre-Bertrand1, C Exbrayat, J Liautard
1Service des Maladies du Sang, C.H.U., Montpellier, France.
Insights
Interleukin-6 receptor (IL-6R) is expressed on chronic lymphocytic leukemia (CLL) cells. Soluble IL-6R (sIL-6R) levels are elevated in CLL, lymphoma, and monoclonal gammopathy patients, correlating with disease stage.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- The interleukin-6 receptor (IL-6R) plays a critical role in IL-6 signaling pathways.
- Dysregulation of IL-6R expression and its soluble form (sIL-6R) are implicated in various hematological malignancies.
Purpose of the Study:
- To investigate the membrane expression of IL-6R on neoplastic cells in chronic lymphocytic leukemia (CLL) and B-cell lymphomas.
- To quantify serum levels of soluble IL-6R (sIL-6R) in CLL, non-Hodgkin's lymphoma (NHL), and monoclonal gammopathy (MG) patients.
- To explore potential correlations between sIL-6R levels and disease characteristics.
Main Methods:
- Quantitative flow cytometry was employed to assess membrane IL-6R expression on CLL and lymphoma cells using monoclonal antibodies.
- Reverse transcription polymerase chain reaction (RT-PCR) was utilized to detect IL-6R specific mRNA in neoplastic cells.
- An enzyme-linked immunosorbent assay (ELISA) was developed to measure sIL-6R concentrations in patient serum samples.
Main Results:
- IL-6R was detected on neoplastic cells in a significant proportion of CLL and lymphoma cases.
- Serum sIL-6R levels were significantly elevated in patients with CLL, NHL, and MG compared to healthy controls.
- Higher sIL-6R levels were observed in high-grade NHL and in CLL patients at Binet stage B, suggesting a correlation with tumor burden.
Conclusions:
- Neoplastic cells in CLL and some lymphomas express IL-6R, indicating potential responsiveness to IL-6 signaling.
- Elevated serum sIL-6R is a common finding in these hematological malignancies and may serve as a biomarker.
- sIL-6R levels correlate with disease severity in CLL and NHL, highlighting its potential role in disease progression.
Abstract:
We studied the membrane expression of the gp80 chain of IL-6 receptor (IL-6R) by quantitative flow cytometry in chronic lymphocytic leukaemia (CLL) and leukaemic centrocytic lymphoma using a panel of seven monoclonal antibodies. IL-6R was detected in 18/26 CLL cases and 4/7 lymphoma cases, with a mean antigen density < 3000 molecules/cell. Multiple labelling experiments confirmed the IL-6R expression by neoplastic cells. Specific mRNA was found by RT-PCR in neoplastic cells. A specific ELISA test was designed using two anti-IL-6 receptor MAbs to measure the serum soluble IL-6R (sIL-6R) in CLL (n = 48). B-cell non-Hodgkin's lymphoma (NHL; n = 40), and monoclonal gammopathy (MG; n = 32). SIL-6R was higher in CLL (170 +/- 12.6 ng/ml) in NHL (160 +/- 12 ng/ml) and MG patients (183 +/- 23 ng/ml) than in age-matched controls (100 +/- 5.6 ng/ml; P < 0.001) and higher in high-grade than low-grade NHL. No correlation was noted with a previous treatment. Among CLL cases the patients classified as stage B according to the Binet's staging of the disease had the highest sIL-6R values, thus suggesting a link with tumour cell mass.
